Vaxcyte, Inc. filings document a clinical-stage vaccine company developing bacterial-disease vaccine candidates and raising capital through registered common stock transactions. Recent Form 8-K reports cover financial results, business updates tied to VAX-31 and other pipeline programs, an underwritten common stock offering, an at-the-market sales agreement under an effective Form S-3 shelf registration, and a manufacturing services agreement for drug product supply.
Proxy materials disclose shareholder voting matters, board and governance information, executive compensation, and equity-plan matters. The filing record also identifies Vaxcyte’s Nasdaq-listed common stock under PCVX and formalizes material agreements, financing arrangements, and corporate disclosures related to its vaccine development and manufacturing strategy.
Vaxcyte, Inc. (PCVX) is the issuer of common stock that officer James Wassil plans to sell under Rule 144. A notice covers a proposed sale of 1,381 shares through UBS Financial Services Inc., with an aggregate market value of $82,487.13 as of September 4, 2026, on NASDAQ.
The notice also lists prior sales by James Wassil of 2,250 shares on July 1, 2026 for $126,735.98, 2,250 shares on August 3, 2026 for $121,194.45, and 3,477 shares on September 1, 2026 for $212,352.66. The securities to be sold were acquired by RSU vesting on September 2, 2026 from the issuer.
Vaxcyte, Inc. (PCVX) announced senior leadership changes and clarified key clinical timelines. On August 31, 2026, the company appointed David McAvoy as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary, while Mikhail Eydelman continues as Senior Vice President, General Counsel. In a related press release, Vaxcyte also named Luis Jodar, Ph.D., a long-time vaccines leader at Pfizer, as Chief Medical Officer.
The company stated that topline safety, tolerability and immunogenicity data from the VAX-31 adult Phase 3 OPUS-1 pivotal trial are now expected by the end of October 2026, narrowing prior guidance that data would be shared in the fourth quarter of 2026. Vaxcyte plans to report Phase 3 data from OPUS-2 and OPUS-3 in the first half of 2027 and is preparing for a planned Biologics License Application submission and potential commercialization of VAX-31, its 31-valent pneumococcal conjugate vaccine candidate.
Vaxcyte, Inc. (PCVX) chief operating officer Jim Wassil reported an option exercise and related share transactions. On September 1, 2026 he exercised 2,250 stock options at $5.35 per share into common stock, then sold 3,477 shares around $61 per share in open-market transactions under a Rule 10b5-1 trading plan. On August 31 and September 2, 2026, a total of 2,705 shares of common stock were withheld or surrendered at prices near $61 solely to cover tax liabilities from vesting RSUs. Following the exercise, Wassil held 66,648 stock options of the same series directly.
Vaxcyte, Inc. (PCVX) director and chief executive officer Grant Pickering reported two Form 4 transactions involving Common Stock that were dispositions solely to cover tax withholding on vested restricted stock units. On August 31, 2026, 2,862 shares were surrendered at $60.74 per share, and on September 2, 2026, 3,427 shares were surrendered at $61.58 per share, both to the issuer for tax obligations. No Rule 10b5-1 trading plan is reported, and additional shares are held indirectly through trusts for the benefit of his son and daughter.
Vaxcyte, Inc. (PCVX) reported that its president and chief financial officer, Andrew Guggenhime, had 2,705 shares of common stock surrendered on August 31 and September 2, 2026 to cover tax withholding obligations arising from the vesting of restricted stock units. These dispositions were made by delivering or withholding shares rather than through open-market sales, and no Rule 10b5-1 trading plan is reported. Separately, 61,850 shares of common stock are shown as held indirectly through ALG 2025 GRAT HOLDINGS LLC, a grantor retained annuity trust–related entity for which Guggenhime is annuitant and trustee.
Vaxcyte, Inc. (PCVX) reported that Chief Technical Ops Officer Harpreet S. Dhaliwal surrendered shares of common stock to the company to cover tax withholding on vested RSUs. On August 31, 2026, 361 shares were withheld at $60.74 per share, and on September 2, 2026, 659 shares were withheld at $61.58 per share. These are non-market, code F transactions, and no Rule 10b5-1 trading plan is reported.
Vaxcyte, Inc. (PCVX) reported that Elvia Cowan, SVP, Finance & CAO, had two Form 4 transactions consisting of shares of common stock surrendered to cover tax withholding on vested restricted stock units. On August 31 and September 2, 2026, a total of 569 shares were withheld for this purpose.
Vaxcyte, Inc. (PCVX) has a notice under Rule 144 for planned sales of common stock for the account of officer James Wassil, with UBS Financial Services, Inc. as broker. The notice covers the potential sale of 3,477 shares of common stock with an aggregate market value of $209,628.33. Vaxcyte reports 148,805,278 shares of common stock outstanding as of September 1, 2026. In the prior three months, Wassil reported sales of 2,250 shares on each of June 1, July 1, and August 3, 2026, for aggregate prices of $111,416.62, $126,735.98, and $121,194.45, respectively.
Janus Henderson Group Ltd. reports significant institutional ownership in Vaxcyte, Inc. common stock. Through its various affiliated asset managers, it may be deemed the beneficial owner of 18,040,375 shares of Vaxcyte, representing 12.1% of the outstanding common stock as of July 31, 2026.
All of these shares are held with shared voting and shared dispositive power; there is no sole voting or dispositive power. The shares are owned in client accounts referred to as Managed Portfolios, which have the right to receive all dividends and sale proceeds, and none of the individual Managed Portfolios owns more than five percent of Vaxcyte’s common stock.
Janus Henderson Group Ltd. filed an amended Schedule 13G reporting beneficial ownership of common stock of Vaxcyte, Inc.. Through its asset management subsidiaries acting on behalf of client accounts (Managed Portfolios), Janus Henderson may be deemed to beneficially own 65,694 shares of Vaxcyte common stock, representing 0.1% of the class.
The filing states that Janus Henderson has no sole voting or dispositive power over these shares, but shared voting and shared dispositive power over 65,694 shares via its Asset Managers. The Managed Portfolios, not Janus Henderson, have the right to receive all dividends and sale proceeds, and none of the individual Managed Portfolios own more than five percent of Vaxcyte’s common stock.